Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

AdvancedAdvT set to end year ahead of expectations

(Sharecast News) - AdvancedAdvT said in an update on Thursday that full-year trading for the period ending 28 February was expected to be materially ahead of market expectations, driven by strong customer growth and improved contract renewals. The AIM-traded software solutions provider highlighted sustained recurring revenue growth and operational efficiencies as key factors behind its outperformance.

It said it had built on the momentum from its interim results in November, benefiting from both new business wins and the renewal of substantial contracts on improved terms.

The company said it would provide further details when it publishes its audited full-year results in July.

"Our strong performance reflects the operational changes implemented in the first half of the year and the positive impact of key customer contract wins," said chair Vin Murria.

"These factors provide a solid foundation for continued growth.

"We remain focused on delivering long-term value for our shareholders and continue to pursue further merger and acquisition targets."

At 1131 GMT, shares in AdvancedAdvT were up 10.95% at 160.88p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.